Inactive Instrument

NicOx SA Stock Euronext Paris

NCOX

FR0000074130

News in other languages: NicOx SA

10-30	Bourse : Amazon et Intel se font pulvériser, Capgemini et Sanofi assurent
10-30	Nicox réduit nettement sa perte au premier semestre 2026 et sécurise sa trésorerie jusqu'en 2028
10-30	Alphabet, Amazon, Intel… c'est plus ce que c'était !
10-30	Nicox publie les résultats financiers du premier semestre 2026
09-16	Nicox va présenter des données sur le NCX 470 lors d'un congrès

More news

Managers and Directors: NicOx SA

Manager	Title	Age	Since
Gavin Spencer CEO	Chief Executive Officer	55	28/02/2024
Sandrine Gestin DFI	Director of Finance/CFO	58	01/01/2015
Emmet Purtill PRN	Corporate Officer/Principal	-	01/01/2006

Director	Title	Age	Since
Gavin Spencer BRD	Director/Board Member	55	08/04/2024
Damian Marron CHM	Chairman	64	16/07/2024
Marc Bozec BRD	Director/Board Member	-	16/07/2024

More insiders

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NICOX SA	-7.95%	-9.39%	-	-	27.72M
ELI LILLY AND COMPANY	+0.61%	+10.62%	+58.16%	+149.73%	1,255B
JOHNSON & JOHNSON	+3.81%	+2.82%	+48.35%	+82.58%	641B
ABBVIE INC.	+3.09%	+2.95%	+39.10%	+108.48%	505B
ROCHE HOLDING AG	+1.25%	-0.78%	+52.56%	+66.87%	381B
MERCK & CO., INC.	+3.93%	+6.02%	+82.28%	+45.44%	357B
NOVARTIS AG	+2.10%	+4.26%	+34.93%	+61.10%	303B
ASTRAZENECA PLC	+1.92%	+9.37%	+13.43%	+36.55%	286B
AMGEN INC.	+3.73%	+6.82%	+61.48%	+77.31%	249B
GILEAD SCIENCES, INC.	+4.19%	+9.68%	+42.96%	+113.85%	208B
Average	+1.67%	+2.95%	+48.14%	+82.43%	465.02B
Weighted average by Cap.	+2.30%	+3.90%	+50.61%	+97.79%

See all sector performances

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Employees

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	24.81M 27.86M 22.76M 20.68M 38.92M 2.63B 39.77M 271M 109M 1.4B 105M 102M 4.41B	P/E 2026 *	-5.63x	P/E 2027 *	14.1x
Enterprise Value	24.81M 27.86M 22.76M 20.68M 38.92M 2.63B 39.77M 271M 109M 1.4B 105M 102M 4.41B	EV / Sales 2026 *	8.27x	EV / Sales 2027 *	2.48x
Free-Float	90.36%	Yield 2026 *	-	Yield 2027 *	-

10-30	Nicox sharply narrows first-half 2026 loss and secures cash runway through 2028
10-30	Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
09-16	Nicox to present NCX 470 data at a conference
09-11	Chinese Regulator Accepts Nicox's Glaucoma Drug Application for Review	MT
09-11	Nicox S.A. Announces Acceptance Of NCX 470 NDA For Review In China	CI
09-11	Nicox wins regulatory acceptance in China
09-02	Nicox S.A. Announces Appointment of Doug Hubatsch as Chief Scientific Advisor	CI
08-27	The FDA will issue its decision on Nicox's NCX 470 by the end of next April
08-27	US FDA to Complete Nicox's Glaucoma Drug Review by April 2027	MT
08-27	Nicox S.A. Announces U.S. Food and Drug Administration Accepts the New Drug Application for NCX 470	CI
08-10	Nicox Sa and Ocumension Therapeutics Submit Ncx 470 New Drug Application in China	CI
08-10	Nicox Partner Files China Drug Application for NCX 470 Eye Drop	MT
08-10	A Nicox partner has cleared an important milestone in China

10-30	Nicox Reports First Half 2026 Financial Results	GL
09-16	Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026	GL
09-11	Nicox Announces NCX 470 NDA in China Accepted for Review	GL
09-02	Nicox Announces Extension of Cash Runway	GL
08-27	Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma	GL

	2026 *	2027 *
Net sales	3M 3.37M 2.75M 2.5M 4.71M 319M 4.81M 32.79M 13.16M 169M 12.64M 12.37M 534M	10M 11.23M 9.17M 8.33M 15.69M 1.06B 16.03M 109M 43.86M 563M 42.12M 41.23M 1.78B
Net income	-5M -5.61M -4.59M -4.17M -7.84M -531M -8.02M -54.64M -21.93M -281M -21.06M -20.62M -889M	2M 2.25M 1.83M 1.67M 3.14M 212M 3.21M 21.86M 8.77M 113M 8.42M 8.25M 356M
Net Debt	-	-

NicOx SA Stock Euronext Paris

Stocks

NCOX

FR0000074130

Pharmaceuticals

Valuation: NicOx SA

Latest news: NicOx SA

Press Releases: NicOx SA

News in other languages: NicOx SA

Quotes and Performance

Managers and Directors: NicOx SA

Specialty & Advanced Pharmaceuticals

Financials

Company Profile